PulseSight Therapeutics

PulseSight is an ophthalmic drug development company that leverages minimally invasive delivery technology to develop disruptive non-viral gene therapies, aiming to meet the unmet needs for treating severe retinal diseases that cause blindness. The focus is on age-related macular degeneration (AMD), including wet AMD and geographic atrophy (GA) in advanced dry AMD.